Every time you receive a mandate to increase a company’s revenue, remember that if you do it without thinking about it carefully, you could kill the goose that lays the golden eggs.
It seems that everyone agrees to say that increasing a company's revenue solves many problems. When Private Equity Funds - which usually are focused on increasing revenue over profits - face profitability problems, the common train of thought is "we have to grow to get out of this trouble." However, if not done correctly, they might end up killing the goose that lays the golden eggs.
Read the full article written by A&M Managing Director Floris Iking.
Copyright 2020, Alto Nivel Magazine. Original article published here.
Navigating Global Pharma Policy
January 26, 2026
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could be felt across the global healthcare landscape. For an industry already grappling with rising R&D costs and competitive pressures, these tariffs threaten to erode profit margins and disrupt finely tuned supply chains.
The State of Transformation for U.S. Healthcare Providers
January 26, 2026
Market dynamics for health systems are shifting. The most significant driver is the federal Medicaid mandate, which expired at the end of December 2025 and is now pending legislation. This uncertainty is prompting health system leaders to rethink strategy and operations. In this context, we’ll share how other health systems are responding and what these changes mean for organizations like yours.
ALVAREZ & MARSAL GLOBAL TRANSACTION ADVISORY GROUP ANNOUNCES 15 MANAGING DIRECTOR PROMOTIONS
January 26, 2026
Alvarez & Marsal (A&M) Global Transaction Advisory Group (Global TAG) today announced the promotion of 15 professionals to Managing Director, reflecting the firm’s continued investment in client service excellence and internal talent development on a global growth path.
Alvarez & Marsal advises NIBC on an LP-led secondary transaction
January 23, 2026
A&M advised NIBC on a successful LP-led secondary transaction involving the sale of a portfolio of private equity fund interests to De Wereld van Vermaat, through its fund investment arm, M Eight.
